SUTRO BIOPHARMA, INC. Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 16 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-09-18: Reporting owner Gerber Hans-Peter; Form 4; Security Restricted Stock Units (RSUs); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-06-02: Reporting owner Chow Gregory K.; Form 4; Security Restricted Stock Units (RSUs); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-03-04: Reporting owner Pauling David; Form 4; Security Restricted Stock Units (RSUs); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-03-04: Reporting owner Chung Jane; Form 4; Security Restricted Stock Units (RSUs); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
STRO insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-09-18 | Gerber Hans-Peter Officer (CHIEF SCIENTIFIC OFFICER) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,750 3,750 owned after | $0.00 | $15.34 | 2026-09-22 |
| 2026-06-02 | Chow Gregory K. Officer (CFO) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 7,500 owned after | $0.00 | $24.43 | 2026-06-02 |
| 2026-03-04 | Pauling David Officer (Chief Admin. Ofcr. & GC) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −675 0 owned after | $0.00 | $21.31 | 2026-03-06 |
| 2026-03-04 | Chung Jane Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −788 0 owned after | $0.00 | $21.31 | 2026-03-06 |
| 2026-03-02 | Pauling David Officer (Chief Admin. Ofcr. & GC) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,356 7,069 owned after | $0.00 | $20.55 | 2026-03-03 |
| 2026-03-02 | Pauling David Officer (Chief Admin. Ofcr. & GC) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,200 4,200 owned after | $0.00 | $20.55 | 2026-03-03 |
| 2026-03-02 | Gerber Hans-Peter Officer (CHIEF SCIENTIFIC OFFICER) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,843 8,532 owned after | $0.00 | $20.55 | 2026-03-03 |
| 2026-03-02 | Gerber Hans-Peter Officer (CHIEF SCIENTIFIC OFFICER) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $0.00 | $20.55 | 2026-03-03 |
| 2026-03-02 | Chow Gregory K. Officer (CFO) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $0.00 | $20.55 | 2026-03-03 |
| 2026-03-02 | Chung Jane Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,750 23,250 owned after | $0.00 | $20.55 | 2026-03-03 |
| 2026-03-02 | Chung Jane Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $0.00 | $20.55 | 2026-03-03 |
| 2026-03-01 | Pauling David Officer (Chief Admin. Ofcr. & GC) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −500 500 owned after | $0.00 | $20.47 | 2026-03-03 |
| 2026-03-01 | Pauling David Officer (Chief Admin. Ofcr. & GC) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −842 1,686 owned after | $0.00 | $20.47 | 2026-03-03 |
| 2026-03-01 | Gerber Hans-Peter Officer (CHIEF SCIENTIFIC OFFICER) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,125 2,250 owned after | $0.00 | $20.47 | 2026-03-03 |
| 2026-03-01 | Chung Jane Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −688 688 owned after | $0.00 | $20.47 | 2026-03-03 |
| 2026-03-01 | Chung Jane Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Units (RSUs) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | $20.47 | 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |